Intralesional injection of OK-432 for vision-threatening orbital lymphangioma

Jinsook Yoon, Jung Bum Choi, Sung Joo Kim, Sang Yeul Lee

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background Surgical excision of orbital lymphangiomas is difficult, and almost always incomplete due to the diffusely infiltrative pattern of these tumors. The present report describes the successful use of intralesional OK-432 administration to treat two patients with intractable hemorrhagic proptosis due to orbital lymphangiomas. Methods A 3-year-old girl (case 1) presented with aggressive proptosis and ptosis, and a 1-year-old boy (case 2) presented with massive proptosis and exposure keratopathy, associated with recurrent intracystic bleeding of an orbital lymphangioma. In case 1, 0.02 mg OK-432 was intracystically injected in a volume of 2 ml of physiologic saline. Due to a lack of therapeutic response, a second injection of 0.05 mg OK-432 in 1 ml was administered. In case 2, a single dose of 0.05 mg OK-432 in 1 ml was administered. Results In both cases, intracystic administration of 0.05 mg of OK-432 in a 1-ml volume resulted in a successful outcome. The adverse effects were minor (mild transient fever and lid swelling), and rebleeding and intraocular pressure elevation did not occur. Proptosis and eyelid swelling gradually improved over 1 month, and completely resolved within 3 months of treatment. Conclusions Intralesional administration of 0.05 mg/ml OK-432 (delivered in 1 ml) resulted in the successful treatment of two cases of orbital lymphangioma. Although this drug concentration is higher than in previous reports, there were no major adverse effects.

Original languageEnglish
Pages (from-to)1031-1035
Number of pages5
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume245
Issue number7
DOIs
Publication statusPublished - 2006 Jul 1

Fingerprint

Intralesional Injections
Picibanil
Lymphangioma
Exophthalmos
Eyelids
Intraocular Pressure
Fever
Therapeutics
Hemorrhage
Injections
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Yoon, Jinsook ; Choi, Jung Bum ; Kim, Sung Joo ; Lee, Sang Yeul. / Intralesional injection of OK-432 for vision-threatening orbital lymphangioma. In: Graefe's Archive for Clinical and Experimental Ophthalmology. 2006 ; Vol. 245, No. 7. pp. 1031-1035.
@article{5e6fef5ab3ed4c179beb905a63eeb62e,
title = "Intralesional injection of OK-432 for vision-threatening orbital lymphangioma",
abstract = "Background Surgical excision of orbital lymphangiomas is difficult, and almost always incomplete due to the diffusely infiltrative pattern of these tumors. The present report describes the successful use of intralesional OK-432 administration to treat two patients with intractable hemorrhagic proptosis due to orbital lymphangiomas. Methods A 3-year-old girl (case 1) presented with aggressive proptosis and ptosis, and a 1-year-old boy (case 2) presented with massive proptosis and exposure keratopathy, associated with recurrent intracystic bleeding of an orbital lymphangioma. In case 1, 0.02 mg OK-432 was intracystically injected in a volume of 2 ml of physiologic saline. Due to a lack of therapeutic response, a second injection of 0.05 mg OK-432 in 1 ml was administered. In case 2, a single dose of 0.05 mg OK-432 in 1 ml was administered. Results In both cases, intracystic administration of 0.05 mg of OK-432 in a 1-ml volume resulted in a successful outcome. The adverse effects were minor (mild transient fever and lid swelling), and rebleeding and intraocular pressure elevation did not occur. Proptosis and eyelid swelling gradually improved over 1 month, and completely resolved within 3 months of treatment. Conclusions Intralesional administration of 0.05 mg/ml OK-432 (delivered in 1 ml) resulted in the successful treatment of two cases of orbital lymphangioma. Although this drug concentration is higher than in previous reports, there were no major adverse effects.",
author = "Jinsook Yoon and Choi, {Jung Bum} and Kim, {Sung Joo} and Lee, {Sang Yeul}",
year = "2006",
month = "7",
day = "1",
doi = "10.1007/s00417-006-0510-4",
language = "English",
volume = "245",
pages = "1031--1035",
journal = "Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie",
issn = "0065-6100",
publisher = "Springer Verlag",
number = "7",

}

Intralesional injection of OK-432 for vision-threatening orbital lymphangioma. / Yoon, Jinsook; Choi, Jung Bum; Kim, Sung Joo; Lee, Sang Yeul.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 245, No. 7, 01.07.2006, p. 1031-1035.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intralesional injection of OK-432 for vision-threatening orbital lymphangioma

AU - Yoon, Jinsook

AU - Choi, Jung Bum

AU - Kim, Sung Joo

AU - Lee, Sang Yeul

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Background Surgical excision of orbital lymphangiomas is difficult, and almost always incomplete due to the diffusely infiltrative pattern of these tumors. The present report describes the successful use of intralesional OK-432 administration to treat two patients with intractable hemorrhagic proptosis due to orbital lymphangiomas. Methods A 3-year-old girl (case 1) presented with aggressive proptosis and ptosis, and a 1-year-old boy (case 2) presented with massive proptosis and exposure keratopathy, associated with recurrent intracystic bleeding of an orbital lymphangioma. In case 1, 0.02 mg OK-432 was intracystically injected in a volume of 2 ml of physiologic saline. Due to a lack of therapeutic response, a second injection of 0.05 mg OK-432 in 1 ml was administered. In case 2, a single dose of 0.05 mg OK-432 in 1 ml was administered. Results In both cases, intracystic administration of 0.05 mg of OK-432 in a 1-ml volume resulted in a successful outcome. The adverse effects were minor (mild transient fever and lid swelling), and rebleeding and intraocular pressure elevation did not occur. Proptosis and eyelid swelling gradually improved over 1 month, and completely resolved within 3 months of treatment. Conclusions Intralesional administration of 0.05 mg/ml OK-432 (delivered in 1 ml) resulted in the successful treatment of two cases of orbital lymphangioma. Although this drug concentration is higher than in previous reports, there were no major adverse effects.

AB - Background Surgical excision of orbital lymphangiomas is difficult, and almost always incomplete due to the diffusely infiltrative pattern of these tumors. The present report describes the successful use of intralesional OK-432 administration to treat two patients with intractable hemorrhagic proptosis due to orbital lymphangiomas. Methods A 3-year-old girl (case 1) presented with aggressive proptosis and ptosis, and a 1-year-old boy (case 2) presented with massive proptosis and exposure keratopathy, associated with recurrent intracystic bleeding of an orbital lymphangioma. In case 1, 0.02 mg OK-432 was intracystically injected in a volume of 2 ml of physiologic saline. Due to a lack of therapeutic response, a second injection of 0.05 mg OK-432 in 1 ml was administered. In case 2, a single dose of 0.05 mg OK-432 in 1 ml was administered. Results In both cases, intracystic administration of 0.05 mg of OK-432 in a 1-ml volume resulted in a successful outcome. The adverse effects were minor (mild transient fever and lid swelling), and rebleeding and intraocular pressure elevation did not occur. Proptosis and eyelid swelling gradually improved over 1 month, and completely resolved within 3 months of treatment. Conclusions Intralesional administration of 0.05 mg/ml OK-432 (delivered in 1 ml) resulted in the successful treatment of two cases of orbital lymphangioma. Although this drug concentration is higher than in previous reports, there were no major adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=35748944587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748944587&partnerID=8YFLogxK

U2 - 10.1007/s00417-006-0510-4

DO - 10.1007/s00417-006-0510-4

M3 - Article

C2 - 17577592

AN - SCOPUS:35748944587

VL - 245

SP - 1031

EP - 1035

JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

SN - 0065-6100

IS - 7

ER -